ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Real-World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large-Scale Post‑Marketing Surveillance Study.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionAcquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan.
aimThis post-marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly assess effectiveness, for AHA patients in clinical practice in Japan.
methodsThis post-marketing surveillance study is being conducted in patients with AHA who receive emicizumab and immunosuppressive therapy (IST). For each patient, the observation period is from the first day of emicizumab to 4 weeks after the last administration, up to 24 months. The primary endpoint is adverse events (AEs).
resultsThe first 51 patients who completed the survey were included in this interim analysis; 34 (66.7%) were male, and the median (range) age was 76.0 (33-91) years. Twenty-five (49.0%) patients experienced 63 AEs (45 serious). One thromboembolism occurred: cerebral infarction, unrelated to emicizumab. Nine (17.6%) patients died, due to infection (n = 4), haemorrhage (n = 3) and 'other' (n = 2), with no causal relationship with emicizumab in any case. Excluding the Week 1 emicizumab loading dose period, 8 (15.6%) patients received recombinant FVIIa while on emicizumab. All patients received IST from Day 1 (median initial prednisolone dose: 0.93 mg/kg). Median FVIII activity (one-stage assay) reached ∼60% in the patients who completed emicizumab treatment, and continued increasing after completion.
conclusionsThis post-marketing study confirmed that emicizumab is well tolerated in patients with AHA, with no unexpected safety concerns. The benefit-risk profile of emicizumab remains favourable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.